Day: March 25, 2020

Amsterdam, 25 March 2020 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) today announced that it has successfully placed €600 million of 5-year Notes with a coupon of 1.625% and €800 million of 10-year Notes with a coupon of 2.25%.The Notes will be issued under the Company’s Euro Medium Term Note Programme and will be listed on the Luxembourg Stock Exchange.The proceeds from the Notes issuance will be used for general corporate purposes. The maturity dates of the Notes are 30 March 2025 and 30 March 2030.Banca IMI, BNP Paribas, Credit Suisse, Deutsche Bank and HSBC acted as book runners.On 18 March 2020, Heineken N.V. also successfully placed CHF 100 million of 5-year Notes with a coupon of 0.6375% privately.ENDSPress enquiries                                             Tim van der Zanden / Michael Fuchs                                          ...

Measures related to Covid-19In today’s rapidly-changing environment, our priorities are the health and safety of our employees as well as the protection of our company, focusing on business continuity, cash flow generation and management of operating expenses. Business Continuity Plans have been implemented at central and country level. The vast majority of our distribution centers and branches are up and running and able to respond to customer needs, including emergency maintenance for critical activities such as hospitals, the food & beverage industry and the power sector. We are encouraging our customers to use our digital and telephone platforms.We have taken the following measures to be in a position to better navigate this challenging environment and capture the full benefits of a recovery when it materializes:The Board of...

 ___________________________________________________________________________________________Mesures liées au Covid-19 _______________________________________________________________________________________Dans l’environnement actuel en évolution constante, nos priorités sont la santé et la sécurité de nos employés et la préservation de notre entreprise, avec une attention particulière portée à la continuité de nos activités, la génération de trésorerie et la gestion de nos coûts opérationnels. Des plans de continuité d’activité ont été déployés aux niveaux du Groupe et des pays. La plupart de nos centres de distribution et de nos agences sont ouverts et opérationnels afin de répondre aux besoins de nos clients, notamment les interventions de maintenance des activités critiques telles que les hôpitaux, l’industrie agroalimentaire ou le...

                    YLEISELEKTRONIIKKA OYJ  PÖRSSITIEDOTE  25.3.2020 klo 19.30YLEISELEKTRONIIKKA OYJ:N YHTIÖKOKOUSKUTSU Yleiselektroniikka Oyj:n osakkeenomistajat kutsutaan varsinaiseen yhtiökokoukseen, joka pidetään torstaina 16.4.2020 klo 16.00 yhtiön pääkonttorissa, osoitteessa Luomannotko 6, 02200 Espoo.A. YHTIÖKOKOUKSESSA KÄSITELTÄVÄT ASIATYhtiökokouksessa käsitellään seuraavat asiat:1. Kokouksen avaaminen2. Kokouksen järjestäytyminen3. Pöytäkirjantarkastajien ja ääntenlaskun valvojien valitseminen4. Kokouksen laillisuuden toteaminen5. Läsnäolevien toteaminen ja ääniluettelon vahvistaminen6. Vuoden 2019 tilinpäätöksen, toimintakertomuksen ja tilintarkastuskertomuksen esittäminen–          Toimitusjohtajan katsaus7. Tilinpäätöksen vahvistaminen8. Taseen osoittaman voiton käyttäminen ja osingonmaksusta päättäminenHallitus ehdottaa...

 Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA; Sets Stage for Phase 3 StudyDevelopment plan towards licensure endorsed with FDAApproval through Accelerated Approval Pathway1 (immunological surrogate)Main Phase 3 trial planned as double-blind, placebo-controlled, multi-center studyDose Selection for Phase 3, manufacturing and industrialization strategy acceptedStudy initiation as soon as COVID-19 situation permitsCurrently anticipated for the fourth quarter 2020Primary endpoint analysis is expected six months thereafterSeamless fit with Valneva’s existing commercial and manufacturing capabilities as a plug and play asset Saint-Herblain (France), March 25, 2020 – Valneva SE (“Valneva” or “the Company”) announced today that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug...

  Valneva : Réunion de fin de Phase 2 positive avec la FDA ouvrant la voie au lancement d’une étude de Phase 3Plan de développement jusqu’à la mise sur le marché du vaccin approuvéValneva bénéficie d’un processus accéléré pour l’obtention d’une autorisation de mise sur le marchéEtude de Phase 3 prévue en double aveugle, contrôlée par placebo et multi-centresDosage du vaccin accepté pour la Phase 3, la production et l’industrialisationInitiation de l’étude dès que la situation liée au COVID-19 le permettraActuellement estimée au quatrième trimestre 2020Analyse du critère principal de l’étude prévue six mois plus tardVaccin s’intégrant parfaitement aux infrastructures commerciales et industrielles existantes de ValnevaSaint-Herblain (France), le 25 mars 2020 – Valneva SE (“Valneva” ou “le Groupe”) a annoncé aujourd’hui une réunion...

Eik fasteignafélag hf. („Eik“ eða „félagið“) hefur vegna áhrifa COVID-19 ákveðið að:fella úr gildi afkomuspá félagsins fyrir árið 2020,fresta aðalfundi hluthafa sem fram átti að fara 2. apríl 2020, ogljúka endurkaupaáætlun félagsins sem tilkynnt var um 10. mars 2020.Breytingar á afkomuspá fyrir árið 2020Eik birti afkomuspá fyrir árið 2020 þann 13. febrúar sl. Forsendur spárinnar breytast dag frá degi vegna mikillar óvissu um áhrif COVID-19 á íslenskt efnahagslíf og er það mat félagsins að forsendur spárinnar séu brostnar.Árið fór vel af stað og var rekstur félagsins fyrstu tvo mánuði ársins lítillega yfir áætlunum. Útlit er fyrir að mars verði nokkuð undir væntingum enda hafa tekjur Hótel 1919 dregist mikið saman. Leitast hefur verið við að draga úr kostnaði hótelsins og kann því að verða lokað tímabundið. Rekstrarkostnaður hótelsins...

March 25, 2020Amsterdam, the Netherlands – Koninklijke Philips N.V. (“Royal Philips”) (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its issue of EUR 500 million fixed rate notes due 2025 and EUR 500 million fixed rate notes due 2030 (together the “Notes”).The net proceeds of the offering are intended for general company purposes and sustainable innovation expenditures as defined in the ESG framework available on the debt section of Philips Investor Relations website, and will further enhance the company’s liquidity position in view of the possible continued impact of the COVID-19 pandemic on financial markets in 2020.The issue price for the notes due 2025 is 99.550% with a Coupon of 1.375%, resulting in a yield of 1.469%. The issue price for the notes due 2030 is 99.204% with a...